Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma
10.12092/j.issn.1009-2501.2021.07.009
- Author:
Jing BAO
1
;
Xiaowen CHEN
1
;
Liang XIA
1
;
Yuchen ZHAO
1
;
Ruixiang XIA
1
;
Hailong XIA
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Anhui Medical University
- Publication Type:Journal Article
- Keywords:
Efficacy;
Ixazomib;
Multiple myeloma;
Safety
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(7):782-786
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To evaluate the clinical efficacy and safety of oral proteasome inhibitor ixazomib in the treatment of multiple myeloma. METHODS: Eighty patients with multiple myeloma treated with ixazomib-containing therapy in the department of hematology, the First Affiliated Hospital of Anhui Medical University from January 2019 to December 2020 were retrospectively analyzed, including 38 patients with relapsed/refractory multiple myeloma (RRMM)and 42 patients who switched treatment due to adverse events (AEs) after initial induction therapy with bortezomib. Treatment was a two-drug or three-drug regimen containing ixazomib, and the clinical efficacy and safety of ixazomib were evaluated. RESULTS: The overall response rate (ORR) of relapsed/refractory patients was 50%, ≥ VGPR 21.05%; the ORR of patients who switched treatment was 83.33%, compared with the ORR before switching (78.57%), the response rate was further improved, of which 45.24%(19/42) patients had deepened response; the main hematological AEs included granulocyte and platelet count reduction and anemia, non-hematological AEs were mainly diarrhea and fatigue. CONCLUSION: Ixazomib shows good clinical efficacy and safety in patients with RRMM and bortezomib-intolerant MM.
